IL253907B - Dihydro-4h-pyrazolo[5, 1, –c][1, 4] oxazinyl fused compounds and their analogues for the treatment of CNS disorders - Google Patents
Dihydro-4h-pyrazolo[5, 1, –c][1, 4] oxazinyl fused compounds and their analogues for the treatment of CNS disordersInfo
- Publication number
- IL253907B IL253907B IL253907A IL25390717A IL253907B IL 253907 B IL253907 B IL 253907B IL 253907 A IL253907 A IL 253907A IL 25390717 A IL25390717 A IL 25390717A IL 253907 B IL253907 B IL 253907B
- Authority
- IL
- Israel
- Prior art keywords
- pyrazolo
- analogs
- cns disorders
- treating cns
- oxazinyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562115043P | 2015-02-11 | 2015-02-11 | |
| PCT/US2016/017527 WO2016130790A1 (en) | 2015-02-11 | 2016-02-11 | Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL253907A0 IL253907A0 (en) | 2017-10-31 |
| IL253907B true IL253907B (en) | 2020-09-30 |
Family
ID=55456906
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL253907A IL253907B (en) | 2015-02-11 | 2017-08-08 | Dihydro-4h-pyrazolo[5, 1, –c][1, 4] oxazinyl fused compounds and their analogues for the treatment of CNS disorders |
| IL277658A IL277658B (en) | 2015-02-11 | 2020-09-29 | Dihydro-4h-pyrazolo[5, 1, –c][1, 4] oxazinyl fused compounds and their analogues for the treatment of CNS disorders |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL277658A IL277658B (en) | 2015-02-11 | 2020-09-29 | Dihydro-4h-pyrazolo[5, 1, –c][1, 4] oxazinyl fused compounds and their analogues for the treatment of CNS disorders |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US9758529B2 (https=) |
| EP (3) | EP3539967A1 (https=) |
| JP (4) | JP6561128B2 (https=) |
| KR (1) | KR102623321B1 (https=) |
| CN (2) | CN111171047B (https=) |
| AU (4) | AU2016219247B2 (https=) |
| BR (1) | BR112017017349B1 (https=) |
| CA (1) | CA2976092A1 (https=) |
| DK (1) | DK3256476T3 (https=) |
| EA (1) | EA201791802A1 (https=) |
| ES (1) | ES2712627T3 (https=) |
| IL (2) | IL253907B (https=) |
| MX (1) | MX371197B (https=) |
| NZ (1) | NZ734972A (https=) |
| PH (1) | PH12017501423A1 (https=) |
| PL (1) | PL3256476T3 (https=) |
| PT (1) | PT3256476T (https=) |
| SG (1) | SG11201706516WA (https=) |
| UA (1) | UA123262C2 (https=) |
| WO (1) | WO2016130790A1 (https=) |
| ZA (1) | ZA201706074B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111171047B (zh) * | 2015-02-11 | 2023-06-23 | 赛诺维信制药公司 | 用于治疗cns障碍的稠合二氢-4h-吡唑并[5,1-c][1,4]噁嗪基化合物 |
| CA3032141A1 (en) | 2016-07-29 | 2018-02-01 | Vadim ALEXANDROV | Compounds and compositions and uses thereof |
| UA125519C2 (uk) | 2016-07-29 | 2022-04-13 | Суновіон Фармасьютікалз Інк. | Сполуки і композиції і їх застосування |
| KR101753092B1 (ko) | 2016-12-14 | 2017-07-04 | 성일하이텍(주) | 리튬 함유 폐액으로부터 인산리튬 제조방법 |
| US10850989B2 (en) | 2016-12-20 | 2020-12-01 | Sungeel Hitech Co., Ltd. | Method for preparing solid lithium salt from lithium solution |
| CN121221782A (zh) | 2017-06-30 | 2025-12-30 | 傲拓神经科学公司 | 用于治疗抑郁的nk-1拮抗剂组合物和方法 |
| BR112020001433A2 (pt) | 2017-08-02 | 2020-07-28 | Sunovion Pharmaceuticals Inc. | compostos de isocromano e usos dos mesmos |
| WO2019236808A1 (en) | 2018-06-07 | 2019-12-12 | Sunovion Pharmaceuticals Inc. | Salts of a oxazino[4,3-b]indazole derivative and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| MX2021010880A (es) | 2019-03-14 | 2022-01-18 | Sunovion Pharmaceuticals Inc | Sales de un compuesto de isocromanilo y formas cristalinas, procesos de preparacion, usos terapeuticos y composiciones farmaceuticas de las mismas. |
| TW202237622A (zh) * | 2020-12-04 | 2022-10-01 | 美商蘇諾維恩藥業公司 | 雜環化合物的鹽及其晶型、製備方法、治療用途與醫藥組合物 |
| WO2022217233A1 (en) * | 2021-04-08 | 2022-10-13 | Sunovion Pharmaceuticals Inc. | Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders |
| EP4416133A1 (en) * | 2021-10-11 | 2024-08-21 | Baylor College of Medicine | G-protein-coupled receptor regulators and methods of use thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3995052A (en) * | 1973-07-09 | 1976-11-30 | Ayerst Mckenna And Harrison Ltd. | Indenopyran- and indenothiopyranalkylamines III in the treatment of depression |
| US4041169A (en) * | 1975-03-05 | 1977-08-09 | Ayerst Mckenna And Harrison Ltd. | Pharmaceutical method for using pyrano-and thiopyranoindole derivatives |
| MX2008013053A (es) * | 2006-04-12 | 2008-10-17 | Wyeth Corp | Derivados de dihidri[1,4]oxazino[2,3,4-hi]indazol-sustituidos como ligandos de 5-hidroxitriptamina-6. |
| KR20110132564A (ko) * | 2009-02-11 | 2011-12-08 | 선오비온 파마슈티컬스 인코포레이티드 | 히스타민 ｈ3 역 작용제 및 길항제, 및 이의 사용 방법 |
| CN106883246B (zh) * | 2009-12-04 | 2020-05-29 | 桑诺维恩药品公司 | 多环化合物及其使用方法 |
| CN103313989B (zh) * | 2010-12-16 | 2016-05-04 | 霍夫曼-拉罗奇有限公司 | 三环pi3k抑制剂化合物和使用方法 |
| KR20140082765A (ko) * | 2011-10-05 | 2014-07-02 | 에프. 호프만-라 로슈 아게 | V1a 길항제로서의 사이클로헥실-4H,6H-5-옥사-2,3,10b-트라이아자-벤조[e]아줄렌 |
| WO2013067248A1 (en) * | 2011-11-04 | 2013-05-10 | Vertex Pharmaceuticals Incorporated | Benzoxazines as modulators of ion channels |
| AU2012357169B2 (en) * | 2011-12-22 | 2017-03-30 | Merck Patent Gmbh | Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators |
| CN104797255A (zh) * | 2012-06-20 | 2015-07-22 | 范德比尔特大学 | 作为mglur5受体变构调节剂的取代的双环烷氧基吡唑类似物 |
| JP2014214130A (ja) * | 2013-04-26 | 2014-11-17 | 大正製薬株式会社 | ジヒドロイミダゾオキサゾール誘導体を含有する医薬 |
| CN111171047B (zh) * | 2015-02-11 | 2023-06-23 | 赛诺维信制药公司 | 用于治疗cns障碍的稠合二氢-4h-吡唑并[5,1-c][1,4]噁嗪基化合物 |
| PL3256466T3 (pl) * | 2015-02-11 | 2022-05-23 | Sunovion Pharmaceuticals Inc. | Związki 1-heterocykliloizochromanylu i analogi do leczenia zaburzeń oun |
-
2016
- 2016-02-11 CN CN202010051639.8A patent/CN111171047B/zh not_active Expired - Fee Related
- 2016-02-11 WO PCT/US2016/017527 patent/WO2016130790A1/en not_active Ceased
- 2016-02-11 CN CN201680018684.5A patent/CN107567454B/zh not_active Expired - Fee Related
- 2016-02-11 BR BR112017017349-2A patent/BR112017017349B1/pt not_active IP Right Cessation
- 2016-02-11 EP EP18213435.3A patent/EP3539967A1/en not_active Withdrawn
- 2016-02-11 DK DK16708260.1T patent/DK3256476T3/en active
- 2016-02-11 JP JP2017542400A patent/JP6561128B2/ja not_active Expired - Fee Related
- 2016-02-11 EA EA201791802A patent/EA201791802A1/ru unknown
- 2016-02-11 EP EP16708260.1A patent/EP3256476B1/en active Active
- 2016-02-11 MX MX2017010362A patent/MX371197B/es active IP Right Grant
- 2016-02-11 AU AU2016219247A patent/AU2016219247B2/en not_active Expired - Fee Related
- 2016-02-11 EP EP21198192.3A patent/EP4006039B1/en active Active
- 2016-02-11 PT PT16708260T patent/PT3256476T/pt unknown
- 2016-02-11 US US15/041,827 patent/US9758529B2/en not_active Expired - Fee Related
- 2016-02-11 UA UAA201708954A patent/UA123262C2/uk unknown
- 2016-02-11 ES ES16708260T patent/ES2712627T3/es active Active
- 2016-02-11 KR KR1020177025289A patent/KR102623321B1/ko active Active
- 2016-02-11 PL PL16708260T patent/PL3256476T3/pl unknown
- 2016-02-11 SG SG11201706516WA patent/SG11201706516WA/en unknown
- 2016-02-11 CA CA2976092A patent/CA2976092A1/en active Pending
- 2016-02-11 NZ NZ734972A patent/NZ734972A/en not_active IP Right Cessation
-
2017
- 2017-08-02 US US15/666,719 patent/US20180057506A1/en not_active Abandoned
- 2017-08-08 IL IL253907A patent/IL253907B/en active IP Right Grant
- 2017-08-09 PH PH12017501423A patent/PH12017501423A1/en unknown
- 2017-09-06 ZA ZA2017/06074A patent/ZA201706074B/en unknown
-
2019
- 2019-05-06 US US16/403,734 patent/US20200024286A1/en not_active Abandoned
- 2019-07-22 JP JP2019134260A patent/JP6928629B2/ja not_active Expired - Fee Related
-
2020
- 2020-09-29 IL IL277658A patent/IL277658B/en unknown
- 2020-11-11 AU AU2020267209A patent/AU2020267209A1/en not_active Abandoned
-
2021
- 2021-02-19 US US17/179,477 patent/US20210300942A1/en not_active Abandoned
- 2021-08-06 JP JP2021129696A patent/JP2021183624A/ja not_active Ceased
-
2022
- 2022-10-28 AU AU2022259828A patent/AU2022259828A1/en not_active Abandoned
- 2022-12-02 JP JP2022193341A patent/JP2023036611A/ja not_active Ceased
-
2024
- 2024-06-24 AU AU2024204310A patent/AU2024204310A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL277658B (en) | Dihydro-4h-pyrazolo[5, 1, –c][1, 4] oxazinyl fused compounds and their analogues for the treatment of CNS disorders | |
| IL291533A (en) | Compounds and preparations including them for the treatment of diseases of the central nervous system | |
| IL279308A (en) | Methods for the treatment of heptidine-mediated disorders | |
| IL275506A (en) | Preparations and methods for the treatment of central nervous system disorders | |
| IL275562A (en) | Preparations and methods for the treatment of central nervous system disorders | |
| ZA201707852B (en) | Compounds for use in treating neuromuscular disorders | |
| SMT202100113T1 (it) | Composizioni e metodi per trattare disturbi del snc | |
| PT3206493T (pt) | Composições e métodos para tratamento de transtornos do snc | |
| ME03749B (me) | KOMPOZICIJE I POSTUPCIZA LEČENJE POREMEĆAJA CNS-a | |
| EP3280420A4 (en) | Compositions and methods for treating cns disorders | |
| IL253914B (en) | 1-Heterocyclyl isochromanyl compounds and analogs for the treatment of CNS disorders | |
| IL256350A (en) | Compositions and methods for the treatment of substance use disorders, addiction, and psychiatric disorders | |
| SG10201913400QA (en) | Methods for treating lung disorders | |
| IL259674B (en) | Benzofuran derivatives for the treatment of diseases related to the central nervous system and other diseases | |
| IL259556A (en) | Solid forms of substituted 6,5-dihydro-6-phenyl-benzo[f]isoquinoline-2-amine compounds | |
| PT3420084T (pt) | Nova abordagem para tratamento de disfunções inflamatórias | |
| GB201704130D0 (en) | New process for compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |